Is Retatrutide Safe? Everything from Clinical Trials

Is retatrutide safe? Based on Phase 2 clinical trial data (Jastreboff et al., NEJM 2023), the answer is cautiously encouraging. The triple-agonist drug showed a safety profile broadly comparable to other GLP-1-based medications that are already FDA-approved. No unexpected serious safety signals emerged. But Phase 2 data from 338 participants over 48 weeks is just the beginning — Phase 3 trials with thousands of participants over longer periods will provide the comprehensive safety picture needed for FDA approval.

Phase 2 Safety Summary

The Phase 2 trial enrolled 338 adults with obesity or overweight across multiple dose groups and a placebo group. Here is what the safety data showed:

Common Side Effects (by Dose Group)

Several important patterns emerge from this data:

• Dose-dependent: Side effects were more common at higher doses, which is expected and manageable through gradual dose escalation
• Primarily GI: The side effect profile is dominated by GI symptoms, consistent with other GLP-1 medications
• Usually mild-moderate: Most side effects were rated as mild to moderate in severity
• Transient: Side effects were most common during dose escalation and tended to improve over time

Serious Adverse Events

Serious adverse events (SAEs) — those requiring hospitalization or considered life-threatening — were uncommon in the Phase 2 trial:

• Overall SAE rate: Low and generally similar between treatment and placebo groups
• No deaths attributable to drug: No participant deaths were attributed to retatrutide
• Pancreatitis: No confirmed cases of pancreatitis were reported, though this remains a theoretical risk for all GLP-1-based medications
• Thyroid concerns: Like other GLP-1 drugs, retatrutide carries a theoretical risk of thyroid C-cell tumors based on animal studies. No cases occurred in Phase 2.

Glucagon-Specific Safety Considerations

The glucagon receptor component introduces considerations unique to retatrutide:

Liver Enzymes

Mild, transient elevations in ALT (a liver enzyme) were observed in some participants. This is expected because glucagon directly acts on the liver to promote fat oxidation. These elevations were generally:

• Small in magnitude (within 1-3x the upper limit of normal)
• Transient (resolving with continued treatment)
• Not associated with liver injury or clinical symptoms
• Monitored but not requiring dose adjustment in most cases

Blood Sugar Effects

Glucagon raises blood sugar, which could theoretically be problematic. However, in the Phase 2 trial:

• Hypoglycemia was uncommon in non-diabetic participants
• The GLP-1 and GIP components effectively counterbalanced glucagon's blood sugar effects
• In the diabetic trial, blood sugar was well-controlled with A1C reductions of up to 2.02%

Heart Rate

Small increases in heart rate (2-4 beats per minute) were observed, consistent with other GLP-1 medications. These increases were not clinically significant in the trial population.

Discontinuation Rates

The rate at which participants stopped taking retatrutide due to side effects is an important safety indicator:

• Discontinuation due to adverse events: 6-16% across dose groups
• Comparable to other GLP-1 drugs: Semaglutide trials showed 7-8% discontinuation; tirzepatide showed 4-7%
• Dose-dependent: Higher doses had higher discontinuation rates, as expected

The higher end of the discontinuation range (16% at the highest escalation dose) is somewhat above what is seen with single and dual agonists, but this is expected with the addition of a third receptor. Phase 3 trials with optimized dose escalation may show improved tolerability.

What We Do Not Know Yet

Honest assessment of retatrutide's safety requires acknowledging what Phase 2 data cannot tell us:

• Long-term safety: Phase 2 lasted 48 weeks. We do not know about effects beyond 1 year. Phase 3 trials will provide 72+ weeks of data.
• Rare side effects: With 338 participants, a side effect that occurs in 1 in 1,000 patients would not be detected. Phase 3 trials with thousands of participants can catch rarer events.
• Cardiovascular outcomes: A dedicated cardiovascular outcomes trial is ongoing. Until it is complete, we cannot confirm cardiovascular safety or benefit.
• Real-world safety: Clinical trials have strict inclusion criteria. Real-world patients may have more comorbidities and take more concurrent medications.
• Long-term liver effects: While transient ALT elevations appear benign, long-term glucagon receptor stimulation effects on the liver need extended monitoring.

Putting Safety in Context

Every effective medication has side effects. The relevant question is whether the benefits outweigh the risks. For retatrutide:

• Obesity itself carries serious health risks: cardiovascular disease, type 2 diabetes, cancer, and reduced life expectancy
• The side effects observed with retatrutide are manageable and consistent with an established drug class
• No unexpected safety signals have emerged
• The magnitude of weight loss (24%+) is sufficient to meaningfully reduce obesity-related health risks

Proven Safe Options Available Now

While retatrutide's full safety profile is being established, medications with extensive safety records are available:

• Compounded semaglutide: $99/month — years of real-world safety data from millions of patients
• Compounded tirzepatide: $125/month — proven safety from large-scale trials and growing real-world use

Learn more about how TRIMI ensures safe, quality treatment.